TCRR Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 May 2023 @ 16:00):

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer...

Stats
Today's Volume	3.75M
Average Volume	325 040
Market Cap	58.11M
EPS	$0 ( 2024-03-21 )
Next earnings date	( $0 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.352
ATR14	$0.105 (7.09%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-01	Tang Kevin C	Sell	4 394 800	Common Stock
2023-06-01	Ubs Oncology Impact Fund L.p.	Sell	3 370 982	Common Stock
2023-06-01	Mpm Sunstates Fund, L.p.	Sell	4 158 964	Common Stock
2023-06-01	Mpm Bioventures 2014, L.p.	Sell	4 158 964	Common Stock
2023-06-01	Gadicke Ansbert	Sell	3 370 982	Common Stock

INSIDER POWER
-89.59
Last 99 transactions
Buy: 1 629 400 \| Sell: 23 030 678

Volume Correlation

Long: 0.06 (neutral)

Short: -0.70 (moderate negative)

Signal:(27.338) Neutral

TCR2 Therapeutics Inc Correlation

10 Most Positive Correlations
RMRM	0.89
GAINL	0.889
APOP	0.884
PAIC	0.864
TDAC	0.851
SPRT	0.842
ISNS	0.833
TLGT	0.82
SVAC	0.816

10 Most Negative Correlations
BOCH	-0.936
BNIXU	-0.929
MMAC	-0.891
NETE	-0.87
SHSP	-0.865
AMRB	-0.841
DSPG	-0.816

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

TCR2 Therapeutics Inc Correlation - Currency/Commodity

-0.63
( weak negative )

-0.65
( moderate negative )

0.00
( neutral )

-0.08
( neutral )

-0.36
( neutral )

0.83
( strong )

TCR2 Therapeutics Inc Financials

Annual	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-3.93

Q1	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-1.030

Q4	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-1.560

Q3	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.790

Financial Reports:

No articles found.

TCR2 Therapeutics Inc

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.